230 related articles for article (PubMed ID: 1834166)
1. Activation of human T cells obtained pre- and post-interleukin-2 (IL-2) therapy by anti-CD3 monoclonal antibody plus IL-2: implications for combined in vivo treatment.
Weil-Hillman G; Schell K; Segal DM; Hank JA; Sosman JA; Sondel PM
J Immunother (1991); 1991 Aug; 10(4):267-77. PubMed ID: 1834166
[TBL] [Abstract][Full Text] [Related]
2. Generation propagation, and targeting of human CD4+ helper/killer T cells induced by anti-CD3 monoclonal antibody plus recombinant IL-2. An efficient strategy for adoptive tumor immunotherapy.
Nishimura T; Nakamura Y; Takeuchi Y; Tokuda Y; Iwasawa M; Kawasaki A; Okumura K; Habu S
J Immunol; 1992 Jan; 148(1):285-91. PubMed ID: 1345787
[TBL] [Abstract][Full Text] [Related]
3. Anti-CD3 + IL-2-stimulated murine killer cells. In vitro generation and in vivo antitumor activity.
Anderson PM; Blazar BR; Bach FH; Ochoa AC
J Immunol; 1989 Feb; 142(4):1383-94. PubMed ID: 2521662
[TBL] [Abstract][Full Text] [Related]
4. Bispecific antibody-directed antitumor activity of human CD4+ helper/killer T cells induced by anti-CD3 monoclonal antibody plus interleukin 2.
Nishimura T; Nakamura Y; Takeuchi Y; Gao XH; Tokuda Y; Okumura K; Habu S
Jpn J Cancer Res; 1991 Nov; 82(11):1207-10. PubMed ID: 1836455
[TBL] [Abstract][Full Text] [Related]
5. Interleukin-2-activated murine cell lines with macrophage- and B-lymphoblast-lytic activity.
Suzuki H; Ikemoto M; Yokoyama A; Kamitani T; Yamashita N; Maruyama M; Yano S
Cell Immunol; 1991 Jan; 132(1):127-39. PubMed ID: 1829651
[TBL] [Abstract][Full Text] [Related]
6. Murine anti-CD3 monoclonal antibody induces potent cytolytic activity in both T and NK cell populations.
Stanková J; Hoskin DW; Roder JC
Cell Immunol; 1989 Jun; 121(1):13-29. PubMed ID: 2470516
[TBL] [Abstract][Full Text] [Related]
7. Successful combination immunotherapy for the generation in vivo of antitumor activity with anti-CD3, interleukin 2, and tumor necrosis factor alpha.
Yang SC; Fry KD; Grimm EA; Roth JA
Arch Surg; 1990 Feb; 125(2):220-5. PubMed ID: 2137327
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy with anti-CD3 monoclonal antibodies and recombinant interleukin 2: stimulation of molecular programs of cytotoxic killer cells and induction of tumor regression.
Nakajima F; Khanna A; Xu G; Lagman M; Haschemeyer R; Mouradian J; Wang JC; Stenzel KH; Rubin AL; Suthanthiran M
Proc Natl Acad Sci U S A; 1994 Aug; 91(17):7889-93. PubMed ID: 8058730
[TBL] [Abstract][Full Text] [Related]
9. Anti-CD3 antibody-induced activated killer cells: cytokines as the additional signals for activation of killer cells in effector phase to mediate slow lysis.
Ting CC; Hargrove ME
Cell Immunol; 1991 Jul; 135(2):273-84. PubMed ID: 1828008
[TBL] [Abstract][Full Text] [Related]
10. Induction of suppressor cells to T- and B-cell proliferative responses and immunoglobulin production by monoclonal antibodies recognizing the CD3 T-cell differentiation antigen.
Kunicka JE; Platsoucas CD
Cell Immunol; 1988 Oct; 116(1):195-215. PubMed ID: 2901914
[TBL] [Abstract][Full Text] [Related]
11. Amelioration of experimental lung metastasis in mice by therapy with anti-CD3 monoclonal antibodies.
Hoskin DW; Stankova J; Anderson SK; Roder JC
Cancer Immunol Immunother; 1989; 29(3):226-30. PubMed ID: 2567211
[TBL] [Abstract][Full Text] [Related]
12. Activation via the CD3 and CD16 pathway mediates interleukin-2-dependent autocrine proliferation of granular lymphocytes in patients with granular lymphocyte proliferative disorders.
Hoshino S; Oshimi K; Teramura M; Mizoguchi H
Blood; 1991 Dec; 78(12):3232-40. PubMed ID: 1835892
[TBL] [Abstract][Full Text] [Related]
13. Cellular interactions in effector cell generation and tumor regression mediated by anti-CD3/interleukin 2-activated tumor-draining lymph node cells.
Yoshizawa H; Chang AE; Shu SY
Cancer Res; 1992 Mar; 52(5):1129-36. PubMed ID: 1531321
[TBL] [Abstract][Full Text] [Related]
14. Different mechanisms of activation of proliferating CD3+ cells in patients with lymphoproliferative disease of granular lymphocytes.
Zambello R; Cassatella MA; Trentin L; Bulian P; Siviero F; Feruglio C; Agostini C; Vespignani M; Chisesi T; Pizzolo G
Leukemia; 1991 Nov; 5(11):942-50. PubMed ID: 1835747
[TBL] [Abstract][Full Text] [Related]
15. The role of antibody isotype in IFN-gamma and IL-2 production during anti-CD3-induced T cell proliferation.
Frenken LA; Koene RA; Tax WJ
Transplantation; 1991 Apr; 51(4):881-7. PubMed ID: 1826571
[TBL] [Abstract][Full Text] [Related]
16. Treatment of murine B cell lymphoma with bispecific monoclonal antibodies (anti-idiotype x anti-CD3).
Demanet C; Brissinck J; Van Mechelen M; Leo O; Thielemans K
J Immunol; 1991 Aug; 147(3):1091-7. PubMed ID: 1830596
[TBL] [Abstract][Full Text] [Related]
17. In vivo antitumor activity of anti-CD3-induced activated killer cells.
Yun YS; Hargrove ME; Ting CC
Cancer Res; 1989 Sep; 49(17):4770-4. PubMed ID: 2527087
[TBL] [Abstract][Full Text] [Related]
18. Specific adoptive immunotherapy mediated by tumor-draining lymph node cells sequentially activated with anti-CD3 and IL-2.
Yoshizawa H; Chang AE; Shu S
J Immunol; 1991 Jul; 147(2):729-37. PubMed ID: 1830072
[TBL] [Abstract][Full Text] [Related]
19. The anti-T cell monoclonal antibody 9.3 (anti-CD28) provides a helper signal and bypasses the need for accessory cells in T cell activation with immobilized anti-CD3 and mitogens.
Baroja ML; Lorre K; Van Vaeck F; Ceuppens JL
Cell Immunol; 1989 Apr; 120(1):205-17. PubMed ID: 2539266
[TBL] [Abstract][Full Text] [Related]
20. Lysis of fresh solid tumor targets in the presence of Con A is mediated primarily by Leu 7+ peripheral blood T lymphocytes: blocking by the anti-CD3 monoclonal antibody and comparison with recombinant interleukin 2-induced lysis by natural killer cells.
Itoh K; Platsoucas CD; Tilden AB; Pollock RE; Balch CM
Cell Immunol; 1987 Sep; 108(2):283-96. PubMed ID: 3113741
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
